Three individuals sought medical attention for dangerously low blood sugar in the U.S. in the previous year, having taken suspected fake versions of Novo Nordisk A/S’s (NYSE:NVO) diabetes medication, Ozempic (semaglutide), according to the American Association of Poison Control Centers (AAPCC). Additionally, one person experienced hypoglycemia (low blood sugar) in 2023 after using a compounded version of Ozempic, as reported by the organization, which collaborates with the FDA to address public health risks. Since the rise in demand for Ozempic and its sister medication, Wegovy and Eli Lilly A…